120 related articles for article (PubMed ID: 21509949)
1. Recombinant Lucilia sericata chymotrypsin in a topical hydrogel formulation degrades human wound eschar ex vivo.
Britland S; Smith A; Finter W; Eagland D; Vowden K; Vowden P; Telford G; Brown A; Pritchard D
Biotechnol Prog; 2011; 27(3):870-4. PubMed ID: 21509949
[TBL] [Abstract][Full Text] [Related]
2. Degradation of eschar from venous leg ulcers using a recombinant chymotrypsin from Lucilia sericata.
Telford G; Brown AP; Seabra RA; Horobin AJ; Rich A; English JS; Pritchard DI
Br J Dermatol; 2010 Sep; 163(3):523-31. PubMed ID: 20491762
[TBL] [Abstract][Full Text] [Related]
3. A Jonah-like chymotrypsin from the therapeutic maggot Lucilia sericata plays a role in wound debridement and coagulation.
Pöppel AK; Kahl M; Baumann A; Wiesner J; Gökçen A; Beckert A; Preissner KT; Vilcinskas A; Franta Z
Insect Biochem Mol Biol; 2016 Mar; 70():138-47. PubMed ID: 26773746
[TBL] [Abstract][Full Text] [Related]
4. Maggot chymotrypsin I from Lucilia sericata is resistant to endogenous wound protease inhibitors.
Telford G; Brown AP; Kind A; English JS; Pritchard DI
Br J Dermatol; 2011 Jan; 164(1):192-6. PubMed ID: 21175562
[TBL] [Abstract][Full Text] [Related]
5. Expression of a cGMP compatible Lucilia sericata insect serine proteinase debridement enzyme.
Pritchard DI; Telford G; Diab M; Low W
Biotechnol Prog; 2012; 28(2):567-72. PubMed ID: 22323388
[TBL] [Abstract][Full Text] [Related]
6. Degradation of extracellular matrix components by defined proteinases from the greenbottle larva Lucilia sericata used for the clinical debridement of non-healing wounds.
Chambers L; Woodrow S; Brown AP; Harris PD; Phillips D; Hall M; Church JC; Pritchard DI
Br J Dermatol; 2003 Jan; 148(1):14-23. PubMed ID: 12534589
[TBL] [Abstract][Full Text] [Related]
7. Towards next generation maggot debridement therapy: transgenic Lucilia sericata larvae that produce and secrete a human growth factor.
Linger RJ; Belikoff EJ; Yan Y; Li F; Wantuch HA; Fitzsimons HL; Scott MJ
BMC Biotechnol; 2016 Mar; 16():30. PubMed ID: 27006073
[TBL] [Abstract][Full Text] [Related]
8. [Lucifensin, Chymotrypsin Proteins and Molecular Characterization of Lucilia sericata].
Erdoğan E; Karaca S
Mikrobiyol Bul; 2021 Jan; 55(1):81-90. PubMed ID: 33590983
[TBL] [Abstract][Full Text] [Related]
9. Degradation of MSCRAMM target macromolecules in VLU slough by Lucilia sericata chymotrypsin 1 (ISP) persists in the presence of tissue gelatinase activity.
Pritchard DI; Brown AP
Int Wound J; 2015 Aug; 12(4):414-21. PubMed ID: 23834475
[TBL] [Abstract][Full Text] [Related]
10. Wound debridement potential of glycosidases of the wound-healing maggot, Lucilia sericata.
Telford G; Brown AP; Rich A; English JS; Pritchard DI
Med Vet Entomol; 2012 Sep; 26(3):291-9. PubMed ID: 22620282
[TBL] [Abstract][Full Text] [Related]
11. VenUS II: a randomised controlled trial of larval therapy in the management of leg ulcers.
Dumville JC; Worthy G; Soares MO; Bland JM; Cullum N; Dowson C; Iglesias C; McCaughan D; Mitchell JL; Nelson EA; Torgerson DJ;
Health Technol Assess; 2009 Nov; 13(55):1-182, iii-iv. PubMed ID: 19925723
[TBL] [Abstract][Full Text] [Related]
12. Quality control of a medicinal larval (Lucilia sericata) debridement device based on released gelatinase activity.
Pickles SF; Pritchard DI
Med Vet Entomol; 2017 Jun; 31(2):200-206. PubMed ID: 28117913
[TBL] [Abstract][Full Text] [Related]
13. Blow fly Lucilia sericata nuclease digests DNA associated with wound slough/eschar and with Pseudomonas aeruginosa biofilm.
Brown A; Horobin A; Blount DG; Hill PJ; English J; Rich A; Williams PM; Pritchard DI
Med Vet Entomol; 2012 Dec; 26(4):432-9. PubMed ID: 22827809
[TBL] [Abstract][Full Text] [Related]
14. Maggot excretion products from the blowfly Lucilia sericata contain contact phase/intrinsic pathway-like proteases with procoagulant functions.
Kahl M; Gökçen A; Fischer S; Bäumer M; Wiesner J; Lochnit G; Wygrecka M; Vilcinskas A; Preissner KT
Thromb Haemost; 2015 Aug; 114(2):277-88. PubMed ID: 25948398
[TBL] [Abstract][Full Text] [Related]
15. In vitro evaluation of the association of medicinal larvae (Insecta, Diptera, Calliphoridae) and topical agents conventionally used for the treatment of wounds.
Masiero FS; Silva DG; Luchese M; Estércio T; Pérsio NV; Thyssen PJ
Acta Trop; 2019 Feb; 190():68-72. PubMed ID: 30385217
[TBL] [Abstract][Full Text] [Related]
16. TIME management by medicinal larvae.
Pritchard DI; Čeřovský V; Nigam Y; Pickles SF; Cazander G; Nibbering PH; Bültemann A; Jung W
Int Wound J; 2016 Aug; 13(4):475-84. PubMed ID: 26179750
[TBL] [Abstract][Full Text] [Related]
17. [Biosurgical débridement using Lucilia sericata-maggots - an update].
Nenoff P; Herrmann A; Gerlach C; Herrmann J; Simon JC
Wien Med Wochenschr; 2010 Dec; 160(21-22):578-85. PubMed ID: 20714816
[TBL] [Abstract][Full Text] [Related]
18. Enzymatic debridement for necrotic wounds.
Martin SJ; Corrado OJ; Kay EA
J Wound Care; 1996 Jul; 5(7):310-1. PubMed ID: 8954418
[TBL] [Abstract][Full Text] [Related]
19. The impacts of larval density and protease inhibition on feeding in medicinal larvae of the greenbottle fly Lucilia sericata.
Wilson MR; Nigam Y; Jung W; Knight J; Pritchard DI
Med Vet Entomol; 2016 Mar; 30(1):1-7. PubMed ID: 26463514
[TBL] [Abstract][Full Text] [Related]
20. Crab collagenase in wound debridement.
Glyantsev SP; Adamyan AA; Sakharov Yu
J Wound Care; 1997 Jan; 6(1):13-6. PubMed ID: 9117826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
